ABBV analyst estimates

AbbVie (ABBV) analyst ratings, the average price target and its range, and every firm's latest call.

ABBV analyst ratings and price targets

DateFirmCallTarget
Nov 18, 2026Piper SandlerAbbvie (ABBV) PT Raised to $349 at Piper Sandler$349.00
Nov 4, 2026BMO CapitalAbbvie (ABBV) PT Raised to $315 at Freedom Broker$315.00
Nov 2, 2026UBSAbbvie (ABBV) PT Raised to $295 at UBS$295.00
Nov 2, 2026Wells FargoAbbvie (ABBV) PT Raised to $340 at Wells Fargo$340.00
Nov 2, 2026Canaccord GenuityAbbvie (ABBV) PT Raised to $338 at Canaccord$338.00
Nov 2, 2026GuggenheimAbbvie (ABBV) PT Raised to $322 at Guggenheim$322.00
Nov 2, 2026BernsteinAbbvie (ABBV) PT Raised to $275 at Bernstein SocGen Group$275.00
Nov 2, 2026RBC CapitalAbbvie (ABBV) PT Raised to $330 at RBC Capital; 'Solid Quarter Validates Continued Strong Execution'$330.00
Nov 2, 2026Cantor FitzgeraldAbbvie (ABBV) PT Raised to $325 at Cantor Fitzgerald$325.00
Oct 23, 2026Goldman SachsAbbVie price target raised to $294 from $258 at Goldman Sachs$294.00
Oct 21, 2026BarclaysAbbVie price target raised to $325 from $300 at Barclays$325.00
Oct 8, 2026Cantor FitzgeraldAbbvie (ABBV) PT Raised to $290 at Cantor Fitzgerald$290.00
Oct 7, 2026Morgan StanleyAbbVie price target raised to $310 from $296 at Morgan Stanley$310.00
Oct 6, 2026ScotiabankAbbVie price target raised to $320 from $280 at Scotiabank$320.00
Sep 10, 2026HSBCAbbVie price target raised to $315 from $300 at HSBC$315.00